MARKET

CNCE

CNCE

Concert Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.48
+0.62
+6.29%
Opening 15:10 08/10 EDT
OPEN
9.92
PREV CLOSE
9.86
HIGH
10.49
LOW
9.57
VOLUME
44.19K
TURNOVER
--
52 WEEK HIGH
13.09
52 WEEK LOW
5.36
MARKET CAP
310.77M
P/E (TTM)
-3.4148
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CNCE stock price target is 23.14 with a high estimate of 30.00 and a low estimate of 18.00.

EPS

CNCE News

More
Concert Pharmaceuticals, Inc. (CNCE) CEO Roger Tung on Q2 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 1d ago
Concert Pharma EPS beats by $0.29, beats on revenue
Concert Pharma (NASDAQ:CNCE): Q2 GAAP EPS of -$0.41 beats by $0.29. Revenue of $6.4M (+12700.0% Y/Y) beats by $6.4M. Press Release
seekingalpha · 4d ago
Concert Pharmaceuticals (CNCE) Reports Q2 Loss, Tops Revenue Estimates
Concert (CNCE) delivered earnings and revenue surprises of 39.71% and 63770.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 4d ago
Concert Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Company Update
Concert will host a conference call and webcast today at 8:30 a.m. ET to provide an update on the Company and discuss second quarter 2020 results.
Business Wire · 4d ago
Will Concert Pharmaceuticals (CNCE) Report Negative Q2 Earnings? What You Should Know
Concert (CNCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/30 16:33
Concert Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 6, 2020
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its second quarter 2020 financial results on Thursday, August 6, 2020, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET
Business Wire · 07/30 11:00
Concert Pharma's CTP-543 nabs accelerated review in U.S. for hair loss disorder
The FDA has granted Breakthrough Therapy Designation for Concert Pharmaceuticals' (NASDAQ:CNCE) oral Janus kinase inhibitor, CTP-543, for the treatment of
seekingalpha · 07/08 16:48
Concert Pharmaceuticals Receives FDA Breakthrough Therapy Designation for CTP-543 for the Treatment of Alopecia Areata
Business Wire · 07/08 12:00

Industry

Biotechnology & Medical Research
+0.31%
Pharmaceuticals & Medical Research
+0.17%

Hot Stocks

Symbol
Price
%Change

About CNCE

Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company's deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas. Its product candidates include AVP-786, CTP-656, CTP-730, CTP-543 and JZP-386. The Company's product candidate, CTP-656, is a next generation potentiator that it is initially developing for the treatment of cystic fibrosis in patients having gating mutations, including the G551D mutation. CTP-543 was discovered by applying Concert's deuterium chemistry technology to modify ruxolitinib. AVP-786 is a combination of a dextromethorphan and an ultra-low dose of quinidine. CTP-730 is a phosphodiesterase 4 (PDE4) inhibitor that has potential for the treatment of various inflammatory diseases.
More

Webull offers kinds of Concert Pharmaceuticals Inc stock information, including NASDAQ:CNCE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CNCE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CNCE stock methods without spending real money on the virtual paper trading platform.